Ads
related to: schering plough company catalog
Search results
Results From The WOW.Com Content Network
US$ 18.502 billion (2008) Net income. US$1.903 billion (2008) Parent. Merck & Co. Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent ...
Schering AG. Schering AG was a research-centered German multinational pharmaceutical company headquartered in Wedding, Berlin, which operated as an independent company from 1851 to 2006. In 2006, it was bought by Bayer AG and merged to form the Bayer subsidiary Bayer Schering Pharma AG, which was renamed Bayer HealthCare Pharmaceuticals in 2011 ...
Although Merck & Co. was in reality acquiring Schering-Plough, the purchase was declared a "reverse merger", in which "Old" Merck & Co. was renamed Merck Sharp & Dohme, and Schering-Plough renamed as "Merck & Co., Inc. The maneuver was an attempt avoid a "change-of-control" in order to preserve Schering-Plough's rights to market Remicade.
Organon & Co. Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. [4] Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but gets ...
Merck & Co., Inc. (MRK) announced today that its shareholders voted by an overwhelming 99 percent to approve a proposed $41 billion merger with Schering-Plough Corp. (SGP). Schering-Plough's ...
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Donate; Help; Learn to edit; Community portal; Recent changes; Upload file
In October 2012, Merck & Co. announced that starting in 2014 it would move its headquarters to the Schering-Plough site (formerly belonging to Ciba, Ciba-Geigy and Novartis) in Summit, New Jersey, acquired in the November 2009 acquisition of Schering, and planned to close the Whitehouse Station headquarters building upon completion of the move ...
Originally developed by Schering-Plough, this drug became part of Merck's clinical program, following that company's acquisition of Schering-Plough in 2009. In September 2014 Sun Pharmaceutical acquired worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of US$ 80 million. Upon ...
Ads
related to: schering plough company catalog